Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova最新文献

筛选
英文 中文
[Motor and autonomic disorders influence on pain syndrome of patients with Parkinson's disease of the I-III H&Y stages]. [运动和自主神经障碍对I-III H&Y期帕金森病患者疼痛综合征的影响]
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312304159
A A Pilipovich, O V Vorob'eva
{"title":"[Motor and autonomic disorders influence on pain syndrome of patients with Parkinson's disease of the I-III H&Y stages].","authors":"A A Pilipovich,&nbsp;O V Vorob'eva","doi":"10.17116/jnevro202312304159","DOIUrl":"https://doi.org/10.17116/jnevro202312304159","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the influence of motor and autonomic disorders on the pain of patients with PD of the I-III H&Y stages and possibility of correcting the pain with dopamine receptor agonists (ADR).</p><p><strong>Material and methods: </strong>252 patients (128 women and 124 men, 42-80 years old) with PD of I-III Hoehn and Yahr stages (H&Y) were examined using the following scales: UPDRS, daily activity Sch&En, quality of life PDQ-39, MMSE, BDI, PFS-16, NMSQuest, GSRS, AUA; 53 patients were piribedil treated during 6 months.</p><p><strong>Results: </strong>Our results indicated a wide prevalence of pain syndrome in PD patients (58.6%), starting from the early stages (50% for the Ist stage). The most stable pain associations were found with the PD stage, levodopa doses, severity of motor symptoms (postural disorders and hypokinesia manifestations) and motor complications («off-periods» and dyskinesias), as well as non-motor PD manifestations depression and autonomic dysfunctions (constipation, swallowing disorders, and frequent urination). The regression analysis showed, that the severity of motor complications and depression were the predictors of pain occurrence. The pain syndrome in patients with PD of I-III stages underwent significant regression (by 51% and 62%, after 1.5 and 6 months of therapy, respectively) after ADR (piribedil) addition to their therapy; it's probably due to improving the motor component and decreasing depressive disorders.</p><p><strong>Conclusions: </strong>The piribedil inclusion contributes to the reduction of pain syndrome, regardless is it used in monotherapy or in conjunction with levodopa preparations.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9427364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Multimodal technology in the correction of post-stroke motor disorders]. 多模态技术在脑卒中后运动障碍矫正中的应用
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312303258
L V Petrova, E V Kostenko, I V Pogonchenkova, A V Rylsky, P R Kamchatnov
{"title":"[Multimodal technology in the correction of post-stroke motor disorders].","authors":"L V Petrova,&nbsp;E V Kostenko,&nbsp;I V Pogonchenkova,&nbsp;A V Rylsky,&nbsp;P R Kamchatnov","doi":"10.17116/jnevro202312303258","DOIUrl":"https://doi.org/10.17116/jnevro202312303258","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness of a comprehensive rehabilitation program with the inclusion of programmable FES and BFB-stabilometric training in patients with post-stroke statolocomotor disorders in the late recovery period of ischemic stroke (IS).</p><p><strong>Material and methods: </strong>The study included 120 patients in the late recovery period of IS, 57 women and 63 men, average age 58.4±6.4 years. The duration of the stroke was 228.59±31.9 days. The main group (MG) included 30 patients who underwent FES and BFB-stabilometric training. Comparison group 1 (CG1, <i>n</i>=30) received computer stabilometric training with BFB. Comparison group 2 (CG2, <i>n</i>=30) received FES. The control group (CG3, <i>n</i>=30) received a standard rehabilitation program. MR programs were carried out for all patients in the amount of 15 procedures every other day (5 weeks).</p><p><strong>Results: </strong>The complex of rehabilitation measures with the inclusion of FES and BFB-stabilometric training significantly improve the function of walking in the form of restoration of the motor stereotype by the 5th week of the study, which was confirmed by neurological scales and stabilometry data.</p><p><strong>Conclusions: </strong>The inclusion of FES and BFB-stabilometric training methods in the rehabilitation process leads to earlier motor adaptation of the patient, restoration of impaired balance function and quality of life, which is associated with an increase in plastic and associative processes of the brain.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9175097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Clinical and functional disturbances in epilepsy patients with schizencephaly]. 【癫痫伴裂脑畸形患者的临床与功能障碍】。
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312303146
V I Guzeva, I V Okhrim, O V Guzeva, V V Guzeva, V R Kasumov
{"title":"[Clinical and functional disturbances in epilepsy patients with schizencephaly].","authors":"V I Guzeva,&nbsp;I V Okhrim,&nbsp;O V Guzeva,&nbsp;V V Guzeva,&nbsp;V R Kasumov","doi":"10.17116/jnevro202312303146","DOIUrl":"https://doi.org/10.17116/jnevro202312303146","url":null,"abstract":"<p><strong>Objective: </strong>To study the features of diagnosing and predicting structural epilepsy in children with schizencephaly (SE) based on the analysis of clinical, electrophysiological and neuroimaging results.</p><p><strong>Material and methods: </strong>Fifteen patients with epilepsy and SE (seven boys and eight girls), aged from 3 months to 14 years, were examined.</p><p><strong>Results: </strong>Unilateral SE was detected in ten patients (closed - in four, open - in six), bilateral open SE was detected in five patients. The predominant localization of the anomaly is in the frontal region. In 100% of cases, cognitive and motor impairments of varying severity were detected. In the study group, 11 patients (73.3%) were diagnosed with epilepsy before the age of 6 years. The clinical presentations of epilepsy in children with SE included focal seizures in ten patients (73.3%), epileptic spasms in three patients (20.0%), focal seizures with secondary generalization in five (33.3%), atonic - in one child (6.7%). Refractory epilepsy was noted in 26.7% children with SE, and the absence of positive electroencephalographic changes in 40% of children.</p><p><strong>Conclusions: </strong>The extent of structural brain damage in SE in patients with epilepsy correlates with the degree of cognitive and motor deficits. The form of epilepsy, the semiotics of epileptic seizures, and the effectiveness of antiepileptic therapy do not depend on the type of SE, but correlate with the extent of cortical disorders.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9215108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Possible changes in the electroencephalogram and electrocardiogram after the introduction of peripheral muscle relaxants]. [引入外周肌肉松弛剂后脑电图和心电图可能发生的变化]。
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123031104
A Yu Mikhailov, I Yu Berezina, L I Sumsky, Yu L Arzumanov
{"title":"[Possible changes in the electroencephalogram and electrocardiogram after the introduction of peripheral muscle relaxants].","authors":"A Yu Mikhailov,&nbsp;I Yu Berezina,&nbsp;L I Sumsky,&nbsp;Yu L Arzumanov","doi":"10.17116/jnevro2023123031104","DOIUrl":"https://doi.org/10.17116/jnevro2023123031104","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the changes in the electroencephalogram (EEG) parameters in time, coinciding with the changes recorded by the electrocardiogram (ECG) channel in patients after the introduction of peripheral muscle relaxants.</p><p><strong>Material and methods: </strong>Twenty-four patients were examined in intensive care units on artificial lung ventilation (ALV). During the study, myographic artifacts were recorded in all patients in the EEG, the elimination of which was impossible without the use of pharmacological agents leading to relaxation of muscles - muscle relaxants of peripheral action.</p><p><strong>Results: </strong>Complete suppression of myographic artifacts on the EEG was noted in all patients after the introduction of peripheral muscle relaxants. However, in 4 of them, EEG changes were noted in the period 2 to 3 minutes after the introduction of muscle relaxants and the disappearance of myographic artifacts on the EEG. These changes coincided in time with the changes recorded by the ECG channel.</p><p><strong>Conclusions: </strong>The EEG changes in time, coinciding with the changes in ECG indicators, suggest the presence of short-term disturbances of the functional state of the basic brain systems, probably due to changes in hemodynamics due to cardiac rhythm and conduction disturbances. It is advisable to record the EEG with the inclusion of an ECG channel in the wiring diagram for synchronous recording.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9215111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A complex of B vitamins, choline and inosine in the treatment of chronic pain]. [B族维生素、胆碱和肌苷的复合物,用于治疗慢性疼痛]。
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123041114
M V Putilina
{"title":"[A complex of B vitamins, choline and inosine in the treatment of chronic pain].","authors":"M V Putilina","doi":"10.17116/jnevro2023123041114","DOIUrl":"https://doi.org/10.17116/jnevro2023123041114","url":null,"abstract":"<p><p>Chronic pain is an independent disease associated with multiple changes in the nervous, endocrine and immune systems. The use of B vitamins is pathogenetically justified. Unlike others, the CompligamB complex contains almost all fractions of B vitamins, inosine and para-aminobenzoic acid, which provides an additional therapeutic effect. The effects of vitamins are summarized, in some cases they are potentiated, while none of them can replace the other, so it is advisable to use vitamin complexes.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9415092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Psychopharmacotherapy of mental disorders in hematological patients: security concerns]. [血液病患者精神障碍的精神药物治疗:安全问题]
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312304290
D E Vybornykh, S V Ivanov, E G Gemdzhian, T V Gaponova
{"title":"[Psychopharmacotherapy of mental disorders in hematological patients: security concerns].","authors":"D E Vybornykh,&nbsp;S V Ivanov,&nbsp;E G Gemdzhian,&nbsp;T V Gaponova","doi":"10.17116/jnevro202312304290","DOIUrl":"https://doi.org/10.17116/jnevro202312304290","url":null,"abstract":"<p><strong>Objective: </strong>Evaluation of the safety of psychopharmacotherapy (PFT) of mental disorders in modern protocols for the treatment of patients with blood disorders.</p><p><strong>Material and methods: </strong>The data of medical records of 552 patients with blood disorders who received PFT during treatment at the clinic of the National Medical Research Center for Hematology were analyzed. Any adverse events recorded while taking PFT were taken into account. Statistical analysis included descriptive statistics, frequency analysis, and assessment (Student's t-test) of changes in blood parameters (before and after taking psychotropic drugs).</p><p><strong>Results: </strong>Signs of hematotoxicity were found only in 7.1% (<i>n</i>=37) patients, in all cases while taking benzodiazepines (<i>n</i>=12) in combination with hematotoxic drugs for the treatment of blood disorders. Other significant adverse events (which caused premature discontinuation or dose reduction) were detected in 4.8% (<i>n</i>=25) cases, of which 9 were associated with the appointment of anxiolytics (hydroxyzine, zopiclone), 11 with antidepressants (clomipramine, amitriptyline, duloxetine, trazodone, ademethionine) and 5 with antipsychotics (risperidone, alimemazine, haloperidol).</p><p><strong>Conclusion: </strong>Most psychotropic drugs are effective in relation to psychopathological disorders that develop in hematological patients and are safe when used at minimum/average therapeutic doses within the daily dosage ranges established by the official instructions for use.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Anhedonia in mood disorders and somatic diseases: results of exploratory Mendelian randomization analysis]. [心境障碍和躯体疾病中的快感缺乏:探索性孟德尔随机化分析的结果]。
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312304265
E D Kasyanov, D V Pinakhina, A S Rakitko, E O Vergasova, D P Yermakovich, G V Rukavishnikov, L V Malyshko, Ya V Popov, E V Kovalenko, A Yu Ilinskaya, A A Kim, N A Plotnikov, N G Neznanov, V V Ilinsky, A O Kibitov, G E Mazo
{"title":"[Anhedonia in mood disorders and somatic diseases: results of exploratory Mendelian randomization analysis].","authors":"E D Kasyanov,&nbsp;D V Pinakhina,&nbsp;A S Rakitko,&nbsp;E O Vergasova,&nbsp;D P Yermakovich,&nbsp;G V Rukavishnikov,&nbsp;L V Malyshko,&nbsp;Ya V Popov,&nbsp;E V Kovalenko,&nbsp;A Yu Ilinskaya,&nbsp;A A Kim,&nbsp;N A Plotnikov,&nbsp;N G Neznanov,&nbsp;V V Ilinsky,&nbsp;A O Kibitov,&nbsp;G E Mazo","doi":"10.17116/jnevro202312304265","DOIUrl":"https://doi.org/10.17116/jnevro202312304265","url":null,"abstract":"<p><strong>Objective: </strong>To conduct an exploratory Mendelian randomization analysis of the causal relationships of anhedonia with a wide range of psychiatric and somatic phenotypes based on the genetic data of participants in a population study.</p><p><strong>Material and methods: </strong>This cross-sectional study included 4520 participants, of which 50.4% (<i>n</i>=2280) were female. The mean age was 36.8 (S.D.=9.8) years. Participants were pheno-nailed based on the DSM-5 criteria for anhedonia in the framework of depression. An episode of anhedonia exceeding 2 weeks during life was reported by 57.6% (<i>n</i>=2604) of participants. A genome-wide association study (GWAS) of the anhedonia phenotype was performed, as well as a Mendelian randomization analysis using summary statistics of large-scale GWASs on psychiatric and somatic phenotypes.</p><p><strong>Results: </strong>The GWAS on anhedonia did not reveal the variants with genome-wide significant association (<i>p</i><10<sup>-8</sup>). The most significant (<i>p</i>=9.71×10<sup>-7</sup>) was the variant rs296009 (chr5:168513184) in an intron of the slit guidance ligand 3 (SLIT3) gene. Using Mendelian randomization, nominally significant (<i>p</i><0.05) causal associations of anhedonia with 24 phenotypes were identified, which can be divided into 5 main groups: psychiatric/neurological diseases, inflammatory diseases of the digestive system, respiratory diseases, oncological diseases and metabolic disorders. The most significant causal effects of anhedonia were found for breast cancer (<i>p</i>=0.0004, OR=0.9986, 95% confidence interval (CI) (0.9978-0.999)), minimal depression phenotype (<i>p</i>=0.009, OR=1.004, 95% CI (1.001-1.007)), as well as for apolipoprotein A (<i>p</i>=0.01, OR=0.973, 95% CI (0.952-0.993)) and respiratory diseases (<i>p</i>=0.01, OR=0.9988, 95% CI (0.9980-0.9997)).</p><p><strong>Conclusion: </strong>The polygenic nature of anhedonia may cause the risks of comorbidity of this phenotype with a wide range of somatic diseases, as well as may be associated with mood disorders.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Experience of using rhythmic transcranial magnetic stimulation, extracorporeal shock wave therapy and botulinotherapy in individual motor recovery programs in patients with spastic paresis of the lower limb]. [有节奏经颅磁刺激、体外冲击波治疗和肉毒杆菌素治疗在下肢痉挛性瘫患者个体运动恢复方案中的应用经验]。
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123071118
S E Khatkova, O A Pogoreltseva, V P Dygileva, A S Gilveg, V S Shevchenko, E A Nikolaev, A N Karimov
{"title":"[Experience of using rhythmic transcranial magnetic stimulation, extracorporeal shock wave therapy and botulinotherapy in individual motor recovery programs in patients with spastic paresis of the lower limb].","authors":"S E Khatkova,&nbsp;O A Pogoreltseva,&nbsp;V P Dygileva,&nbsp;A S Gilveg,&nbsp;V S Shevchenko,&nbsp;E A Nikolaev,&nbsp;A N Karimov","doi":"10.17116/jnevro2023123071118","DOIUrl":"https://doi.org/10.17116/jnevro2023123071118","url":null,"abstract":"<p><p>Walking disorder is one of the most frequent consequences of stroke and traumatic brain injury, occurring in 80% of cases. Spastic paresis of the muscles of the lower extremity is the cause formed in 20-40% of patients within a few weeks after brain damage. In this case, a complex of symptoms occurs: motor deficiency (muscle paresis), increased muscle tone (spasticity), biomechanical changes in muscles, joints and surrounding tissues, contractures. Recovery of walking is a difficult task due to the peculiarities of its organization in the norm. At the same time, changes occurring in the muscles of the lower limb after a stroke, their modular reorganization, the formation of various pathological patterns, violation of the regulation of movements by the central nervous system, rapidly occurring changes in muscles, ligaments, complicate this process. Improving walking is one of the most important priorities of rehabilitation. Already at the second (stationary) stage of rehabilitation, patients have a lack of proper support on the lower limb, which inevitably leads to excessive load on the second limb, a change in the body scheme, incorrect foot placement, violation of the mechanics of walking (moving from heel to toe) due to plantar flexion / turn of the foot, etc. All this makes patients dependent on outside help, and walking unsafe, increases the risk of falls and complications (arthropathy, contracture, etc.). In this regard, it is important to timely diagnose the totality of changes in the lower limb and create optimal comprehensive rehabilitation programs using highly effective treatment methods aimed at reducing the severity of the motor defect, reducing spasticity and preventing complications. The article discusses the place of rhythmic transcranial magnetic stimulation, extracorporeal shock wave therapy and botulinum therapy during rehabilitation in patients with spastic paresis of the lower limb after a stroke. The results of the protocol of clinical approbation «Complex rehabilitation of patients with lower limb spasticity after focal brain damage at the second stage of medical rehabilitation» are presented.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Efficacy of potassium N-acetylaminosuccinate (Cogitum) in the treatment of asthenic syndrome: results of double-blind placebo-controlled trial]. [n -乙酰氨基琥珀酸钾(Cogitum)治疗乏力综合征的疗效:双盲安慰剂对照试验结果]。
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro202312306152
R G Esin, I Kh Khayrullin, O R Esin, A F Fatykhova, E I Gismatullina, Yu N Isaeva
{"title":"[Efficacy of potassium N-acetylaminosuccinate (Cogitum) in the treatment of asthenic syndrome: results of double-blind placebo-controlled trial].","authors":"R G Esin,&nbsp;I Kh Khayrullin,&nbsp;O R Esin,&nbsp;A F Fatykhova,&nbsp;E I Gismatullina,&nbsp;Yu N Isaeva","doi":"10.17116/jnevro202312306152","DOIUrl":"https://doi.org/10.17116/jnevro202312306152","url":null,"abstract":"<p><strong>Objective: </strong>Study of the effectiveness of monotherapy with potassium N-acetylaminosuccinate (Cogitum) for asthenic syndrome (fatigue) in individuals, uncharacteristic somatic, neurological diseases, anxiety disorders, depression and other diseases that may interfere with asthenia.</p><p><strong>Material and methods: </strong>Patients with fatigue scores of 22 or more on the Fatigue Assessment Scale (FAS) were randomly divided into the main group (MG) - 37 people, mean age 22 years [21; 24] and the control group (CG) - 34 people, mean age 21 years [19; 23]. The Trail Making Test (TMT-A and TMT-B), the assessment of general well-being on a visual analogue scale (VAS), where 0 is the worst state of health, 10 is the state of absolute well-being, was assessed. MG patients received a solution of potassium N-acetylaminosuccinate (Cogitum) 750 mg per day in a sterile container, CG patients received sterile water with banana flavor in a sterile container. The duration of the study was 21 days.</p><p><strong>Results: </strong>Prior to the start of the study, there were no statistically significant differences in FAS, TMT, and VAS between MG and CG. After 21 days, the FAS score in the MG decreased (<i>p</i>=0.00001), the time of TMT-A (<i>p</i>=0.000012) and TMT-B (<i>p</i>=0.000033) decreased, the VAS score increased (<i>p</i>=0.00024). There were no statistically significant changes in the CG. Placebo effect was noted in 10 patients of the CG (29.4%).</p><p><strong>Conclusion: </strong>Potassium aminosuccinate (Cogitum) at a daily dose of 750 mg and a duration of treatment of 21 days effectively eliminates the symptoms of asthenic syndrome (fatigue), while accompanied by an improvement in complex cognitive functions. The results of our study suggest that fatigue (asthenic syndrome) and cognitive impairment may have a common pathogenetic mechanism - a deficiency of systems in which mediators are N-acetylaspartate and N-acetylaspartylglutamate. Cogitum had no side effects and was well tolerated. Cogitum is superior to placebo in the treatment of fatigue (asthenic syndrome).</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Myasthenic syndrome in a patient with end-stage amyotrophic lateral sclerosis]. [终末期肌萎缩侧索硬化症患者的肌无力综合征]。
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Pub Date : 2023-01-01 DOI: 10.17116/jnevro2023123071102
E A Kovrazhkina, A V Serdyuk, O D Razinskaya, M H Shurdumova, N V Vyatkina, E A Baranova
{"title":"[Myasthenic syndrome in a patient with end-stage amyotrophic lateral sclerosis].","authors":"E A Kovrazhkina,&nbsp;A V Serdyuk,&nbsp;O D Razinskaya,&nbsp;M H Shurdumova,&nbsp;N V Vyatkina,&nbsp;E A Baranova","doi":"10.17116/jnevro2023123071102","DOIUrl":"https://doi.org/10.17116/jnevro2023123071102","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) and myasthenia gravis are diseases with similar clinical features but different prognosis and approach to treatment. It is possible as an extremely rare combination of these diseases, as well as myasthenia gravis with signs of ALS (MuSK-positive), as well as ALS, accompanied by myasthenic syndrome. Latter option is the most common. Myasthenic syndrome accompanying the ALS characterized by pathological muscle fatigue signs, symptoms variability during the day, partial sensitivity to neostigmine, M-wave decrements detection during electromyographyc study. We present a case of a patient with terminal ALS and myasthenic syndrome. The main pathogenesis theories of this condition and the differential diagnosis of ALS and myasthenia gravis are discussed.</p>","PeriodicalId":24030,"journal":{"name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9872262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信